Improving life for women through cancer research

Publications
 
2013

King MT, MR Stockler, P Butow, R O’Connell, M Voysey, AM Oza, K Gillies, HS Donovan, R Mercieca-Bebber, J Martyn, K Sjoquist, and ML Friedlander. Development of the Measure of Ovarian Symptoms and Treatment concerns (MOST): aiming for optimal measurement of patient reported symptom benefit with chemotherapy for symptomatic ovarian cancer. International Journal of Gynaecological Cancer. Accepted for publication 19 Dec 2013.
 
Vergote I, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer C, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed N, Curé H, Pujade-Lauraine E. Randomised phase III study of erlotinib versus 1 observation in patients with no evidence of disease progression after first line platin-based chemotherapy for ovarian carcinoma. An EORTC-GCG and Gynecological Cancer Intergroup study. Journal of Clinical Oncology. Published ahead of print on December 23, 2013 as 10.1200/JCO.2013.50.5669
 
Sjoquist KM, Friedlander ML, O’Connell RL, Voysey M, King MT, Stockler MR, Oza AM, Gillies K, Martyn JK, Butow PN Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecologic Cancer Intergroup Symptom Benefit Study. Oncologist. 2013 Oct 9. [Epub ahead of print] PMID: 24107972
 
Schofield P, Juraskova I, Bergin R, Gough K, Mileshkin L, Krishnasamy M, White K, Bernshaw D, Penberthy S, Aranda S. A nurse and peer led support program to assist women in gynaecological oncology, the PeNTAGOn study (Peer and Nurse support Trial to Assist women in Gynaecological Oncology): protocol for a randomised controlled trial. Trials  2013, 14:39. DOI: 10.1186/1745-6215-14-39 (online publication, 11 February 2013).
 

Price M, Bell M, Sommeijer DW, Friedlander M, Stockler MR; deFazio A; Webb PM, The Australian Ovarian Cancer Study Group, The Australian Ovarian Cancer Study - Quality of Life, Phyllis N Butow. Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: a prospective population-based study over the last year of life. Gynecol Oncol. 2013 Jul;130(1):162-8.

Michael Friedlander and Madeleine King. Patient reported outcomes in ovarian cancer clinical trials. Annals of Oncology (accepted for publication)

Friedlander ML, Stockler MR, Butow P, King MT, McAlpine J, Tinker A, et al. Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? J Clin Oncol. 2013 Jun 20;31(18):2362.
 

Blinman P, Gainford C, Donoghoe M , Martyn J, Blomfield P, Grant P, Kichenadasse V, Vaughan M, Brand A, Shannon K, Gebski V, Stockler MR, Friedlander M. Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: An ANZGOG Study. Journal of Gynecol Oncol 2013 Oct;24(4):359-66. (TRIPOD)

C. K. Lee, R. J. Simes, C. Brown, V. Gebski, J. Pfisterer, A-M. Swart, D. Berton-Rigaud, M. Plante, T. Skeie-Jensen, I. Vergote, C. Schauer, C. Pisano, G. Parma, K. Baumann, J. A. Ledermann, E. Pujade-Lauraine, J. Bentley, G. Kristensen, A. Belau, M. Nankivell, U. Canzler, S. J. Lor1, C. Kurzeder & M. Friedlander. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol (2013) 24 (4): 937-943. (CALYPSO)

Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G,Lamont A,Hindley A,Goss G, Gilby E, Hogg M, Harper P, Kipps E, Lewsley LA, Hall M, Vasey P, Kaye SB. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol (2013) 24 (3): 679-687

Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Friedlander M, Chenevix-Trench G, Antoniou AC; CIMBA. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27. (GOG 199)

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013 Mar;14(3):236-43. doi: 10.1016/S1470-2045(12)70567-3. Epub 2013 Jan 18.

You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Rienthaller A, Pujade-Lauraine E, Oza A. The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). Gynecologic Oncology 2013; 130(2): 289–294.

Sommeijer DW, Sjoquist KM, Friedlander M. Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature. Current Oncology Reports 2013; 15(541–548). (PARAGON)

Grimison PS, Stockler MR, Chatfield M, Thomson DB, Gebski V, Friedlander M, Boland AL, Houghton B, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong SS, Lewis CR, Vasey PA, Toner GC, Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology. In press.

2012

Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Phillips K, Chenevix-Trench G; kConFab investigators, Offit K, Simard J; Consortium of Investigators of Modifiers of BRCA1/2. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20. (GOG 199)
 
Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Phillips KA, Chenevix-Trench G; Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat. 2012 Apr;33(4):690-702. doi: 10.1002/humu.22025. Epub 2012 Feb 14. (GOG 199)
 
Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Kirk J, Chenevix-Trench G, Couch FJ, Simard J, Easton DF; CIMBA, SWE-BRCA; HEBON; EMBRACE; GEMO Collaborators Study; kConFab Investigators. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res. 2012 Feb 20;14(1):R33. (GOG 199)

Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, Skailes G, Lamont A, Hindley A, Goss G, Gilby E, Hogg M, Harper P, Kipps E, Lewsley LA, Hall M, Vasey P, Kaye SB. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol. 2012 Oct 5.
 
Brundage, M., Gropp, M., Mefti, F., Mann, K., Lund, B., Gebski, V., Wolfram, G., Reed, N., Pignata, S., Ferrero, A., Brown, C., Eisenhauer, E., and Pujade-Lauraine, E. (2012) Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.  Ann Oncol 23, 2020-2027.

Tang, A., Kondalsamy-Chennakesavan, S., Ngan, H., Zusterzeel, P., Quinn, M., Carter, J., Leung, Y., and Obermair, A. (2012) Prognostic value of elevated preoperative serum CA125 in ovarian tumors of low malignant potential: A multinational collaborative study (ANZGOG0801).  Gynecol Oncol 126, 36-40.

Wagner, U., Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M. C., Fossati, R., Gebski, V., and Lauraine, E. P. (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.  Br J Cancer 107, 588-591.

Alexandre, J., Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J., Chalchal, H., Fitzharris, B., Volgger, B., Vergote, I., Pisano, C., Ferrero, A., and Pujade-Lauraine, E. (2012) CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.  Br J Cancer 106, 633-637.

Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., Helland, H., Elit, L., and Mahner, S. (2012) Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 23, 1185-1189.

Viswanathan, A. N., Creutzberg, C. L., Craighead, P., McCormack, M., Toita, T., Narayan, K., Reed, N., Long, H., Kim, H. J., Marth, C., Lindegaard, J. C., Cerrotta, A., Small, W., Jr., and Trimble, E. (2012) International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys 82, 250-255.

2011

Brand A. 2011 Ovarian Cancer Debulking Surgery: A Survey of Practice in Australia and New Zealand. Int J Gynecol Cancer. 2011 21:230-235. IF: 1.733
 
Friedlander M, Trimble T, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim J, W, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011 May;21(4):750-5.
 

Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M , Reinthaller A, Vergote I, Ferrandina G, Dell'anna T, Huober J, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol. 2011 Aug;122(2):226-32. IF: 3.760

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol. 2011 22(11) 2417-2423. IF: 6.452

Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer. 2011 Jul 26;105(3):360-5. IF: 4.831

Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, et al. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer. 2011 Oct 11;105(8):1144-50. IF: 4.831

Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, et al. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42. IF:14.697
 
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stahle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K., and Oza, A. M. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365;Dec(26), 2484-2496.
 
Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Dagae S, Greven K, Pamar M, Friedlander M, Cervantes A, Vermoken J. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011 Feb;21(2):419-23. IF: 1.733
 
Sjoquist, KM, Martyn JK, Edmondson RJ, Friedlander ML, The role of hormonal therapy in gynecological cancers-current status and future directions. Int J Gynecol Cancer. 2011 Oct;21(7): 1328-33. IF: 1.733
 

Stuart GC, Kitchener H, Bacon M, Dubois A, Friedlander M, Ledermann J, Marth C, Thigben T, Trimble E. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011 May;21(4):750-5. IF: 1.733

Thigpen T, Dubois A, McAlpine J, Disaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC. First-Line Therapy in Ovarian Cancer Trials. Int J Gynecol Cancer. 2011 May;21(4):756-62. IF: 1.733
 
2010

Friedlander M, editor. Does Palliative Chemotherapy Palliate? Assessment of Symptom Benefit in Recurrent Ovarian Cancer. American Society of Clinical Oncology; 2010; Chicago, IL.
 

Friedlander M. Optimally debulked stage III ovarian cancer: intraperitoneal or intravenous chemotherapy? Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S20-3. IF: 1.733

Friedlander M. Symptom Benefit and Symptom Control in Patients with Recurrent Ovarian Cancer. In: Poveda A, editor. 100 Key Questions in Ovarian Cancer: Permaneyer Publications; 2010. p. 91-101.

 

Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010 Jul 10;28(20):3323-9.

2009

Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, de Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009 Mar 20;27(9):1419-25.
 

Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, Donavan HS, Miller B, King M. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S44-8.

Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, Eisenhauer E, Fitzgerald TJ, Lacomeb D, Parmar M, Seibel N, Shankar L, Swart AM, Therasse P, Vikram B, von Frenckell R, Friedlander M, Fujiwara K, Kaplan RS, Meunier F. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol. 2009 Oct 20;27(30):5109-14.

2008

Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):594-604. (GOG 199 study, ANZGOG acknowledgement)

2007

Gaffney DK, Du Bois A, Narayan K, Reed N, Toita T, Pignata S, Blake P, Portelance L, Sadoyze A, Potter R, Colombo A, Randall M, Mirza MR, Trimble EL. Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):485-90.
 

Tinker AV, Gebski V, Fitzharris B, Buck M, Stuart-Harris R, Beale P, Goldrick A, Rischin D. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01. Gynecol Oncol. 2007 Mar;104(3):647-53.

2005

du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer, E, Friedlander M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel  R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U. 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16 Suppl 8:viii7-viii12.
 

Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, Neijt J. History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004. Ann Oncol. 2005;16 Suppl 8:viii5-viii6.

Quinn M, Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A, Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauranine E, Trimble E, Vasey P, Wagner U. Integration of new or experimental treatment options and new approaches to clinical trials. Ann Oncol. 2005;16 Suppl 8:viii30-viii5.

Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlander M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermoken J, Wagner U. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Ann Oncol. 2005;16 Suppl 8:viii36-viii8.

Abstracts

2011

Michael Friedlander, Merryn Voysey, Madeleine King, Martin Stockler,  Amit M Oza, Kim Gillies, Brigitte Miller, Heidi Donovan, Julie Martyn, Katrin Sjoquist, Rachel O’Connell and Phyllis Butow. Symptom burden and outcomes in patients with platinum resistant/refractory recurrent ovarian cancer (PRR-OC).Results of Stage 1 of the GCIG Symptom Benefit Study (SBS). European Society of Gynaecological Oncology Annual Meeting, Milan, Italy, Sept 2011.
 

Michael Friedlander, Katrin M Sjoquist, Merryn Voysey, Madeleine King, Kim Gillies, Martin Stockler, Julie Martyn, Amit M Oza, Philip Beale, Stephen Begbie, Lisa M Tinker, Dahlia Tsoref, Phyllis Butow on behalf of Australia and New Zealand Gynaecological Oncology Group (ANZGOG), Psycho-oncology Co-operative Research Group (PoCoG), Gynecologic Cancer InterGroup (GCIG) . Hope or Hype – Predictors of benefit from palliative chemotherapy in platinum resistant ovarian cancer. European Society of Gynaecological Oncology Annual Meeting, Milan, Italy, Sept 2011.

Friedlander M, Stockler M, King M, Oza A, Voysey M, Martyn J, Gillies K, Sjoquist K, Butow P. Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer:  the Symptom Benefit study (ANZGOG-0701/ GCIG/PoCoG). American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Grimison PS, Thomson DB, Stockler MR, Chatfield MD, Friedlander M, Gebski V, Boland AL, Houghton BB, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong SS, Lewis CR, Vasey PA, Toner GC. Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Kristensen G, Perren T, Qian W, Pfisterer  J, Ledermann J, Joly F, Carey M S, Beale PJ, Cervantes A, Oza AM, GCIG 2011. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Mahner S, Meier W, Du Bois A, Brown C, Lorusso D, Ferrero A, Cretin J, Havensteen H, Bessette P, Angleitner-Boubenizek L, Vergote IB, Vasey PA, Gebski V, Slama B, Herrstedt J, Kaizer L, Georgoulopoulos A, Reed N, Wagner U. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

Marth C, Alexandre J, Hanker L, Brown C, Kaem J, Heywood M, Bonaventura A, Vergote I, Pignata S, Ferrero AM, Gebski V, Gropp M, Skeie-Jensen T, Giede C, Vasey P, Schauer C, Reed N, Ferrandina G, Fossati R, Pujade-Lauraine E. Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin  in platinum-sensitive ovarian cancer patients: treatment at recurrence and overall survival final analysis from CALYPSO phase III GCIG trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata, S, Fossati R, Emons G, Rehman KL, Steffensen KD, Petru E, Gebski V, Burges A, Tubiana-Matthieu N, Hansen M, Vasey PA, Denison U, De Bruyne P, Oza AM. Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2011; Chicago.

2010

Alexandre J, Brown C, Priou F, De Rauglaudre G, Pfisterer J, Maenpaa J Chalchal H, Marth C, Harris B, Vergote I. Should CA 125 still be part of tumour evaluation criteria in ovarian cancer trials? Experience of the GCIG CALYPSO trial. 35th ESMO Congress; 8–12 Oct 2010; Milan. Abstract 4155.

Blinman P, Gainford C, Duric V, Friedlander M, Stockler M. Patients’ preferences for intraperitoneal chemotherapy for advanced ovarian and related cancers: what makes it worthwhile? Australia. International Gynecological Cancer Society, Prague, Czech Republic, Oct 2010

Blinman P, Gainford C, Duric V, Friedlander M, Stockler M. Patients’ preferences for intraperitoneal chemotherapy for advanced ovarian and related cancers before and after treatment: what makes it worthwhile? Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010.

Friedlander M, Voysey M, King M, Stockler M, Oza A, Gillies K, Miller B, Donovan H, Martyn J, Butow P. Symptom burden among patients with platinum resistant/refractory recurrent ovarian cancer: stage 1 of the GCIG Symptom Benefit study. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 165. Abstract 244.

Friedlander M, Voysey M, King M, Stockler M, Oza A, Gillies K, Miller B, Donovan H, Martyn J, Butow P. Symptom burden among patients with platinum resistant/refractory recurrent ovarian cancer: stage 1 of the GCIG Symptom Benefit study. International Gynecologic Cancer Society (IGCS)13th Biennial Meeting; 23–26 Oct 2010; Prague.

Grimison PS, Stockler M, Thomson DB, Friedlander M, Gebski V, Boland AL, Chatfield M, Rosenthal M, Gurney H, Wong SS, Toner GC, Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Accelerated BEP for advanced germ cell tumours: an ongoing multi-centre phase I/II trial. Asian Oncology Summit; 9–11 Apr 2010; Nusa Dua, Bali.

Grimison PS, Thomson DB, Stockler M, Friedlander M, Gebski V, Boland AL, Chatfield M, Rosenthal M, Gurney H, Toner GC; Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Accelerated BEP for advanced germ cell tumours: an ongoing multi-centre phase I/II trial. ASCO Genitourinary Cancers Symposium; 5–7 Mar 2010; San Francisco.

Lee CK, Guardiola E, Hogberg T, Friedlander M, Bentley J, Denison U, Vergote IB, Pisano C, Parma G, Wimberger P. Development of a nomogram to predict progression-free survival in patients with platinum sensitive recurrent ovarian cancer based on the CALYPSO trial. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago. Journal of Clinical Oncology 2010; 28 (7 suppl). Abstract 5105.

Mileshkin L, Khaw P, Blinman P, Stockler M, Kolodziej I, Martyn J, Quinn M, Creutzberg C. Randomized phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial cancer: PORTEC-3. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 176. Abstract 273.

Mileshkin L, Narayan K, Rischin D, Stockler M, King M, Kolodziej I, Martyn J, Friedlander M, Quinn M, Gebski V. A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK Trial. Clinical Oncological Society of Australia (COSA) Annual Scientific Meeting; 9–11 Nov 2010; Melbourne. Asia-Pacific Journal of Clinical Oncology 2010; 6(suppl 3): 176. Abstract 274.

Simes RJ, Lee CK, Mirza MR, Sauthier P, Georgopoulos A, Vergote IB, Ferrandina G, Donadello N, Schmalfeldt B, Delva R. The value of early decrease in CA125 levels as a prognostic or surrogate marker for disease progression in patients with recurrent ovarian cancer. Results from the CALYPSO study. American Society of Clinical Oncology Annual Meeting; 4–8 Jun 2010; Chicago. Journal of Clinical Oncology 2010; 28 (7 suppl). Abstract 5080.

2009

Kaye SB, Vasey P, Rustin G, Pledge s, Williams C, Gabra H, Skailes G, Lamont A, Lewsley L, Paul J; Scottish Gynaecological Cancer Trials Group. Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4). Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 15s. Abstract 5537.

Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, Reinthaller A, Vergote I, Pignata S, Ferrero A,  A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer : CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). Annual Meeting of the American Society of Clinical Oncology; 29 May–2 Jun 2009; Orlando. Journal of Clinical Oncology 2009; 27: 18s. Abstract LBA5509.

Vasey P, Largillier R, Gropp M, Gebski V, Sandvei R, Elit L, Angleitner-Boubezinek L, Reed N, Pignata S, Ferrero AM. A GCIG randomized phase III study of carboplatin and pegylated liposomal doxorubicin vs carboplatin and paclitaxel: CALYPSO results in partially platinum-sensitive ovarian cancer patients. ECCO 15–34th ESMO Multidisciplinary Congress; 20–24 Sep 2009; Berlin. EJC Supplements 2009; 7(3): 11. Abstract 18LBA.

2008

Åvall-Lundqvist E, Wimberger P, Gladieff L, Gebski V, Huober JB, Floquet A, Fitzharris B, Zeimet AG, Heywood M, Schmalfeldt B. Pegylated liposomal doxorubicin-carboplatin vs paclitaxel-carboplatin in relapsing sensitive ovarian cancer: a 500-patient interim safety analysis of the Calypso GCIG Intergroup phase III study. 44th Annual Meeting of the American Society of Clinical Oncology ; 30 May-3 Jun 2008; Chicago. Journal of Clinical Oncology 2008; 26 (May 20). Abstract 5565.

2007

Gainford MC, Friedlander M, Mueller H, Foo S, Duric V, Stockler M. TRIPOD: A single arm phase II trial of intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers (ANZGOG 0601). 35th Annual General Meeting of the Clinical Oncological Society of Australia ; 14-17 Nov 2007; Adelaide.

Back to top